• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Burning Rock Biotech Limited

    2/13/24 5:23:48 PM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    SC 13G 1 ea193271-13glavbio5_burning.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

    Burning Rock Biotech Limited

    (Name of Issuer)

     

    Class A Ordinary Shares, par value $0.0002 per share

    (Title of Class of Securities)

     

    G17173 108**

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
       
    ☐Rule 13d-1(c)
       
    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **This CUSIP number applies to the Class A Ordinary Shares (the “Shares”) of Burning Rock Biotech Limited (the “Issuer”). CUSIP number 12233L 107 applies to the American Depositary Shares (“ADSs”) of the Issuer, each ADS representing one Share.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

     

     

    CUSIP No. G17173 108 Page 2 of 10

     

    1.

    Name of Reporting Person

     

    LAV Biosciences Fund V sub A, L.P. (“LAVVA”)

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,606,060 Shares(1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,606,060 Shares(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,606,060 Shares(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    1.9%(2)

    12.

    Type of Reporting Person (see instructions)

     

    PN

     

    (1)These Class A Ordinary Shares (the “Shares”) of Burning Rock Biotech Limited (the “Issuer”) are beneficially owned through American Depository Shares (“ADSs”). Each ADS represents one (1) Share.

     

    (2)This percentage is calculated based on 85,351,000 Shares outstanding as of December 31, 2023.

     

     

     

     

    CUSIP No. G17173 108 Page 3 of 10

     

    1.

    Name of Reporting Person

     

    LAV Biosciences Fund V, L.P. (“LAVV”)

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,891,145 Shares(1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,891,145 Shares(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,891,145 Shares(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    2.2%(2)

    12.

    Type of Reporting Person (see instructions)

     

    PN

     

    (1)These Class A Ordinary Shares (the “Shares”) of Burning Rock Biotech Limited (the “Issuer”) are beneficially owned through American Depository Shares (“ADSs”). Each ADS represents one (1) Share.

     

    (2)This percentage is calculated based on 85,351,000 Shares outstanding as of December 31, 2023.

     

      

     

     

    CUSIP No. G17173 108 Page 4 of 10

     

    1.

    Name of Reporting Person

     

    LAV Star Limited (“STAR”)

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    British Virgin Islands

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    443,500 Shares(1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    443,500 Shares(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    443,500 Shares(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    0.5%(2)

    12.

    Type of Reporting Person (see instructions)

     

    OO

     

    (1)These Class A Ordinary Shares (the “Shares”) of Burning Rock Biotech Limited (the “Issuer”) are beneficially owned through American Depository Shares (“ADSs”). Each ADS represents one (1) Share.

     

    (2)This percentage is calculated based on 85,351,000 Shares outstanding as of December 31, 2023.

     

      

     

     

    CUSIP No. G17173 108 Page 5 of 10

     

    1.

    Name of Reporting Person

     

    LAV Star Opportunities Limited (“STAR Opportunities”)

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    British Virgin Islands

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    443,500 Shares(1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    443,500 Shares(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    443,500 Shares(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    0.5%(2)

    12.

    Type of Reporting Person (see instructions)

     

    OO

     

    (1)These Class A Ordinary Shares (the “Shares”) of Burning Rock Biotech Limited (the “Issuer”) are beneficially owned through American Depository Shares (“ADSs”). Each ADS represents one (1) Share.

     

    (2)This percentage is calculated based on 85,351,000 Shares outstanding as of December 31, 2023.

     

      

     

     

    CUSIP No. G17173 108 Page 6 of 10

     

    1.

    Name of Reporting Person

     

    Yi Shi

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)


    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,384,205 Shares, 1,606,060 of which are directly owned by LAVVA, 1,891,145 of which are directly owned by LAVV, 443,500 of which are directly owned by STAR, and 443,500 of which are directly owned by STAR Opportunities. Yi Shi, the managing partner of LAVVA, LAVV, STAR and STAR Opportunities, may be deemed to have shared power to vote these shares.(1) 

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,384,205 Shares, 1,606,060 of which are directly owned by LAVVA, 1,891,145 of which are directly owned by LAVV, 443,500 of which are directly owned by STAR, and 443,500 of which are directly owned by STAR Opportunities. Yi Shi, the managing partner of LAVVA, LAVV, STAR and STAR Opportunities, may be deemed to have shared power to vote these shares.(1) 

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,384,205 Shares(1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    5.1%(2)

    12.

    Type of Reporting Person (see instructions)

     

    IN

     

    (1)These Class A Ordinary Shares (the “Shares”) of Burning Rock Biotech Limited (the “Issuer”) are beneficially owned through American Depository Shares (“ADSs”). Each ADS represents one (1) Share.

     

    (2)This percentage is calculated based on 85,351,000 Shares outstanding as of December 31, 2023.

     

      

     

     

    CUSIP No. G17173 108 Page 7 of 10

     

    Item 1(a)   Name of Issuer.
         
        Burning Rock Biotech Limited (the “Issuer”)
         
    Item 1(b)   Address of Issuer’s Principal Executive Offices.
         
       

    No.5 Xingdao Ring Road North, International Bio Island
    Guangzhou, 510005

    People’s Republic of China

         
    Item 2(a)   Name of Persons Filing.
         
       

    This Statement is filed by LAV Biosciences Fund V sub A, L.P. (“LAVVA”), LAV Biosciences Fund V, L.P. (“LAVV”), LAV Star Limited (“STAR”), LAV Star Opportunities Limited (“STAR Opportunities”), and Dr. Yi Shi. The foregoing entities and individual are collectively referred to as the “Reporting Persons.”

     

    Dr. Shi is the managing partner of LAVVA, LAVV, STAR and STAR Opportunities, and may be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by LAVVA, LAVV, STAR and STAR Opportunities,

         
    Item 2(b)   Address of Principal Business Office or, if none, Residence.
         
       

    The address for LAVVA is 2735 Sand Hill Road, Suite 210, Menlo Park, CA 94025.

     

    The address for LAVV, STAR, STAR Opportunities and Dr. Shi is Room 606-7, St. George’s Building, 2 Ice House Street, Central, Hong Kong.

         
    Item 2(c)   Citizenship.
         
       

    LAVVA is a United States partnership. LAVV is Cayman Islands partnership. STAR and STAR Opportunities are British Virgin Islands business companies. Dr. Shi is a United States citizen.

     
    Item 2(d)   Title of Class of Securities.
         
        Class A Ordinary Shares, par value $0.0002 per share
         
    Item 2(e)   CUSIP Number.
         
        G17173 108. This CUSIP number applies to the Class A Ordinary Shares of the Issuer. CUSIP number 12233L 107 applies to the American Depositary Shares of the Issuer, each ADS representing one Class A Ordinary Share.
         
    Item 3   Not applicable.

     

      

     

     

    CUSIP No. G17173 108 Page 8 of 10

     

    Item 4.Ownership.

     

    The following information with respect to the ownership of the Ordinary Shares of the Issuer by the Reporting Persons is provided as of December 31, 2023:

     

    (a)Amount Beneficially Owned:

     

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

     

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Row 8 of cover page for each Reporting Person.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

      

     

     

    CUSIP No. G17173 108 Page 9 of 10

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024 

    LAV BIOSCIENCES FUND V SUB A, L.P.

         
      By: /s/ Yi Shi
      Name:  Yi Shi
      Title: Managing Partner
       
    Dated: February 13, 2024  LAV BIOSCIENCES FUND V, L.P.
         
      By: /s/ Yi Shi
      Name: Yi Shi
      Title: Managing Partner
         
    Dated: February 13, 2024  LAV STAR LIMITED
         
      By: /s/ Yi Shi
      Name: Yi Shi
      Title: Managing Partner
         
    Dated: February 13, 2024  LAV STAR OPPORTUNITIES LIMITED
         
      By: /s/ Yi Shi
      Name: Yi Shi
      Title: Managing Partner
         
    Dated: February 13, 2024  YI SHI
       
     

    By:

    /s/ Yi Shi
     

    Name:

    Yi Shi 

     

     

     

     

    CUSIP No. G17173 108 Page 10 of 10

     

    EXHIBIT INDEX

     

    Exhibit  Found on Sequentially Numbered Page
    Exhibit 99.1: Agreement of Joint Filing   

     

     

     

     

     

     

    Get the next $BNR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Burning Rock Reports First Quarter 2025 Financial Results

      GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma(OSCC)treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, doub

      6/6/25 3:31:54 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

      GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Dete

      3/25/25 7:45:42 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen resumed coverage on Burning Rock Biotech

      Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

      10/15/21 7:18:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • CICC initiated coverage on Burning Rock Biotech with a new price target

      CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

      7/14/21 5:44:04 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Financials

    Live finance-specific insights

    See more
    • Burning Rock Reports First Quarter 2024 Financial Results

      GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

      5/29/24 1:34:06 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

      GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

      5/23/24 2:00:00 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

      GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

      3/28/24 5:16:22 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    See more
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

      GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The AG

      12/3/24 6:45:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2023 Annual General Meeting

      GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor;To re-elect Wendy Hayes,

      12/19/23 9:35:05 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    SEC Filings

    See more
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      6/6/25 6:07:22 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 20-F filed by Burning Rock Biotech Limited

      20-F - Burning Rock Biotech Ltd (0001792267) (Filer)

      4/29/25 6:31:11 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      3/25/25 8:14:01 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      11/14/24 12:29:09 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 4:05:59 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 12:45:51 PM ET
      $BNR
      Medical Specialities
      Health Care